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Abstract
Background: There is a lack of evidence about the effec-
tiveness of cognitive behavior therapies (CBT) in settings
of routine clinical care as well as in the treatment of panic
and comorbid disorders. Methods: We investigated a
group-oriented CBT approach for 80 patients with panic
disorder including 35 patients with current comorbid
major depression. Assessments took place 6 months
before treatment, at the beginning and end of treatment,
and 1 year later. Structured interviews and multiple clini-
cal self-rating scales were used. Results: Panic patients
with comorbid major depression showed higher anxiety-
specific and nonspecific pathology. The most striking
benefits were in reducing avoidance behavior, while
improvements concerning catastrophic beliefs were
smaller, but still significant. For most self-rating scale
results, patients with and without comorbid depression
improved to a comparable degree. However, the end-
state functioning of patients with panic disorder and cur-
rent comorbid depression at admission is significantly
lower than for patients with panic disorder alone. Con-
clusions: The results point to the necessity to develop
and improve treatment approaches for patients with
comorbidity of panic disorder and current major depres-
sion.
Copyright © 2000 S. Karger AG, Basel
Introduction
During the last decade, a number of studies have been
published which postulated that cognitive behavior thera-
py (CBT) is highly effective for the treatment of patient
with panic disorder [1–10]. Despite this vast amount of
evidence for the effectiveness of CBT in panic disorder,
some questions remain open. The described positive
results need to be validated in routine clinical care set-
tings. As Barlow and Lehman [11] pointed out, the ‘trans-
portability’ of treatments like CBT for panic patients to
the health care system as well as the clinical utility is an
unanswered question. Most of the scientific studies on the
effectiveness of CBT were run in research and education
units. This typically implies that the psychotherapists
have an above average motivation to work successfully,
and they receive intensive supervision. In naturalistic
treatment settings, such a frequent supervision is usually
not possible and the grade of motivation may be lower.
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For the introduction of psychopharmacological agents,
a phase 3 (effectiveness in scientific double-blind studies)
is followed by a phase 4 (effectiveness in routine clinical
care). The reason for this procedure is that the effective-
ness of a treatment in scientific studies may not mean that
this treatment is as successful in routine clinical care. Fol-
lowing this reasoning, studies on the effectiveness of psy-
chological treatments in naturalistic settings like these
‘phase 4 studies’ are necessary. However, they are rare.
A further problem arises from the interest in scientific
studies to examine homogeneous groups. Homogeneity of
the samples strengthens possible interpretations but
weakens the generalizability. In fact, in many studies
which focussed on patients with panic disorder, patients
with severe agoraphobia, with additional depression or
drug use were excluded or below 15% [5, 12, 13]. Further
studies excluded depressive patient when depression was
usually poorly defined as ‘primary’. On the other hand,
epidemiological studies demonstrated that comorbidity
in patients with anxiety disorder is not a rare phenome-
non, but is very common [14]. Magee et al. [15] reported
that 46% of persons with agoraphobia have a history of
major depression, and 36% have a history of substance
abuse. Since many persons with panic disorder have a his-
tory of a depressive episode, the generalizability of the
results of treatment studies with low rates of depression is
questionable.
Grunhaus et al. [16] cited that the overlap of anxiety
and depression predicts the worst outcome, including
poor treatment response, more chronicity, higher rates of
agoraphobic avoidance, and higher mortality. O’Rourke
et al. [17] summarized a literature review that in most
(but not all) studies depression was found to have a signif-
icant and negative relationship with outcome. The same
holds true for panic disorder as a possible negative predic-
tor of outcome in the treatment of patients with major
depression [3]. In this study, the negative predictive pow-
er of comorbidity was found for psychological as well as
for psychopharmacological treatment.
In summary, there is a lack of knowledge concerning
the treatment of patients with comorbid panic disorder
and major depression, although this group is of enormous
clinical importance. Thus, the principal aim of the present
study was to investigate the effectiveness of a CBT
approach in the treatment of patients with panic disorder
and comorbid major depression in comparison to patients
without comorbid depression. Secondly, we were inter-
ested in the effectiveness of CBT in a routine clinical care
environment. Therefore, we did not use restrictive inclu-
sion criteria, but tried to include all patients with the diag-
nosis panic disorder. Thirdly, taking the necessity of cost-
effectiveness into account, the central part of the therapy
was a group treatment.
Method
Participants
Patients were recruited from the candidates consecutively ap-
plying for treatment at the Center for Behavioral Medicine, Klinik
Roseneck. All subjects fulfilled the criteria of panic disorder accord-
ing to DSM-III-R [18] (classification procedure see below). From 80
patients fulfilling the criteria for panic disorder, 35 patients also had
current major depression, while 45 patients (56%) had not. Sociode-
mographic variables from the two groups are presented in table 1. As
present-state diagnoses seemed to be more reliable than lifetime diag-
noses, the principal analyses were done comparing patients with
panic disorder with and without current major depression; however,
the subgroup of patients without current major depression, but with
indices of lifetime depression, was also analyzed in final computa-
tions.
Design
All patients included into the study were diagnosed using a stan-
dardized psychiatric interview assessing panic disorder, major de-
pression and multiple other diagnoses (see below). Patients with
panic disorder but without major depression were allocated to group
1, patients with panic disorder and comorbid major depression were
allocated to group 2. Patient acquisition was done as follows: All
patients applying for admission to the Center for Behavioral Medi-
cine, Klinik Roseneck, were asked to send a brief report about cur-
rent symptoms. When the symptom reports contained complaints
such as heart attack, anxiety attack or comparable symptoms, sub-
jects were invited to participate in the study and to fill out further
questionnaires (assessment 1). After a waiting list period of about
6 months (due to organizational reasons, the mean waiting period
was 32.0 weeks), patients were admitted to inpatient treatment. The
first 3 days after admission, subjects were invited to a standardized
psychiatric interview (see below), and were asked to fill out the
instruments of assessment 2. From 109 prescreened patients, 80 ful-
filled the criteria for panic disorder and were motivated to partici-
pate. Exclusion criteria were neurologically significant brain damage,
schizophrenic disorder or treatment goals other than panic manage-
ment. As we intended to include a ‘naturalistic’ sample of patients
asking for treatment, we did not exclude patients with medication
(see Results).
Assessment 3 took place at the end of the treatment. About 1 year
later, subjects were asked to fill out the questionnaires of assessment
4 (follow-up). At follow-up, an additional standardized telephone
interview was conducted to diagnose panic attacks. All 80 patients
included in the study completed at least 3 weeks of treatment; thus
we had no dropouts during treatment, which underlines a high ac-
ceptability of the intervention.
We received questionnaire data at follow-up from 70 of the 80
patients (response rate 88%). We conducted telephone interviews
with 62 patients at follow-up (80%). Principal reasons for missing
data at follow-up were unknown address and/or no telephone at
home.
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Table 1. Group comparison at admission
Variable PD with MD PD without MD Significance
35 45
Age, years 42.9 (10.4) 41.2 (9.1) t = 0.8 (n.s.)
Females, % 71 67 ¯2 = 0.5 (n.s.)
High school or more, % 40 42 ¯2 = 0.1 (n.s.)
Duration of disorder, years 9.1 (8.5) 8.1 (6.9) t = 0.6 (n.s.)
Not able to work during last
12 months, weeks 25.2 (22) 16.7 (29) t = 1.3 (n.s.)
Severe agoraphobic avoidance
(according to DSM-III-R), % 26 32 ¯2 = 0.4 (n.s.)
History of outpatient
psychotherapy, % 60 80 ¯2 = 3.6 (n.s.)
History of inpatient treatment, % 64 40 ¯2 = 4.4 (p ! 0.05)
Psychosocial stress (DSM axis 4) 3.3 (1.3) 2.9 (1.3) t = 1.5 (n.s.)
Agoraphobia, % 91 96 ¯2 = 0.6 (n.s.)
Social phobia, % 23 29 ¯2 = 0.4 (n.s.)
Somatoform disorder, % 26 20 ¯2 = 0.3 (n.s.)
Disability Scale 7.8 (2.4) 6.0 (2.5) F = 9.1 (p ! 0.01)
MI – alone 3.6 (1.1) 2.9 (1.1) F = 6.6 (p ! 0.05)
MI – accompanied 2.9 (1.1) 2.3 (0.9) F = 4.8 (p ! 0.05)
ACQ 2.6 (0.8) 2.1 (0.6) F = 8.6 (p ! 0.01)
BSQ 3.4 (0.7) 2.8 (0.7) F = 8.9 (p ! 0.01)
Depression (CES-D) 35.0 (9.2) 24.3 (9.8) F = 22.6 (p ! 0.001)
Figures in parentheses are SD. PD = Panic disorder; MD = major depression; n.s. = not
significant.
At admission, patients received a complete description of the
study. Afterwards, written informed consent was obtained.
Diagnostic Assessment and Outcome Measures
We used the International Diagnostic Check List (IDCL) as stan-
dardized psychiatric interview for the classification of axis 1 diag-
noses [19]. The interview checks the criteria for more than 30 mental
disorders, including major depression, dysthymia, obsessive-com-
pulsive disorder, alcohol and drug abuse, schizophrenia and somato-
form disorders. This interview was recommended by the World
Health Organization and showed comparable reliability and validity
to other fully standardized instruments [20]. As personality disorders
are difficult to diagnose using cross-sectional assessment, at the end
of treatment, the psychotherapists judged the presence of axis 2 diag-
noses. All psychotherapists were trained in using DSM-IV diagnoses,
but were instructed to diagnose only obviously prominent personali-
ty disorders. At follow-up, a fully standardized interview guideline
was used assessing number of panic attacks as well as symptoms dur-
ing the single attacks for the last 7 days. This time period was also
used in other studies [13]. Further information about course after
discharge were collected, but will not be reported in the present
paper.
As the examination of patients with multiple symptoms was a
major concern of the present study, we did not only use symptom-
specific questionnaires but also measures for global impairment. We
used three items originally described by Marks [21], including work,
family and social impairment. Avoidance was assessed using the
Mobility Inventory (MI) [22] in the ‘alone’ as well as the ‘accompa-
nied’ version. The Agoraphobic Cognition Questionnaire (ACQ) [23]
is a measure for catastrophizing beliefs during states of anxiety. The
Body Sensation Questionnaire (BSQ) [23] assesses fear of multiple
body sensations. These scales were well validated in the English lan-
guage version as well as in the German language version [24]. While
the diagnosis of major depression was assessed using the psychiatric
interview IDCL, the group allocation was further validated using the
Center for Epidemiological Studies Depression Scale (CES-D), which
has proven its clinical usefulness in multiple studies [25, 26]. For the
follow-up assessment, we not only used these rating scales but also a
self-developed questionnaire with items concerning sociodemo-
graphic data, subjective ratings of the ability to work, missing days
at work, medication and further treatments during the follow-up
period.
Statistical Analyses
The first step of statistical analysis will be an ANOVA using one
between factor (two groups) and one within factor (four assessment
points; factor ‘time’). Treatment success should lead to significant
effects or interactions with time. This could be tested with follow-up
analyses comparing the data of admission with the data at discharge,
respectively, with the follow-up data. Therefore, comparisons of
adjacent assessment points are computed in the case of significant
time effects.
As some patients may not fill out the questionnaires completely
and others may drop out, intend-to-treat analyses (ITT) are neces-
sary. For this reason, all data are reanalyzed replacing all missing
values at discharge and at follow-up with the scores at admission.
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This implies the conservative assumption that all patients without
data after treatment are considered as ‘not changed’.
Treatment Setting
The Roseneck Center for Behavioral Medicine is a German inpa-
tient treatment unit which is open to patients of all social and occupa-
tional states. Indications for treatment are all mental and psychoso-
matic disorders except schizophrenia, manic episodes, severe addic-
tions or severe neurological disorders. In Germany, this treatment
setting is typically selected in cases of comorbidity of psychological
and physiological symptoms, in cases of chronic syndromes, or in
cases of a regional lack of outpatient therapists. Thus, it is a setting of
routine clinical care. Physicians, clinical psychologists, and nurses
work together using a behavioral medicine approach. The treatment
costs are covered by all health care insurances.
Treatment Procedure
Panic Management Group. The central part of the treatment was
a manually guided, fully standardized group therapy program for
panic and/or agoraphobic disorders. The training was comparable to
the group treatment package of Telch et al. [8, 9]. The treatment was
comprised of eight 2-hour sessions in groups with about 8 patients.
Furthermore, a guided exposure phase was included. During the first
sessions, patients were informed about biological and psychological
processes during panic attacks, and they developed an individual
psychophysiological model of panic attacks. The hyperventilation
provocation test as well as breathing retraining were also included to
demonstrate psychophysiological interactions and to strengthen the
evidence for the psychophysiological panic model. After exploring a
list of situations where avoidance behavior occurred, an intensive
exposure training followed (about 8 h per patient). The first training
hours were accompanied by a therapist. However, the goal of the
exposure sessions was the patients’ experience that he/she can cope
with intensive panic attacks alone. Therefore, we did not follow a
graded approach, but worked in intensive panic-evoking situations.
The final sessions of the panic management therapy consisted in fur-
ther cognitive restructuring, modifications of catastrophic beliefs
and relapse prevention. The group therapy was typically guided by a
clinical psychologist or trained psychiatrist, the exposure days were
additionally guided by 2–3 psychotherapists or nurses.
Further Treatment. Further standard treatments such as relax-
ation training and problem-solving group were performed if indi-
cated. Patients of both groups did not differ as to the amount of addi-
tional treatments.
Results
Baseline Differences
Table 1 shows baseline differences of the two groups at
admission. There were no significant differences consid-
ering age, sex, education, duration of the disorder, work-
ing disability, degree of agoraphobic avoidance (expert
rating), history of outpatient psychotherapy, psychosocial
stress (expert rating) and comorbidity with agoraphobia,
social phobia or somatoform disorders. In contrast to oth-
er studies, we examined highly chronified samples with a
history of multiple treatment approaches and an extreme
rate of agoraphobia and agoraphobic avoidance. The
results of the self-rating scales were analyzed using the F
statistics of one-way analysis, because these variables are
subjects of further analyses of variance. In all psychomet-
ric scales, the comorbidity group ‘panic disorder with
major depression’ showed significantly higher pathology
than the group with pure panic disorder. That means that
the groups differed not only in variables of depression, but
that the comorbidity group had higher anxiety, avoidance
or disability scores.
Treatment Effects
Table 2 presents the overall results for all question-
naire data. For all variables, strikingly significant effects
for the ANOVA factor time were found. Pairwise compar-
isons of adjacent assessment points revealed that these
effects were mainly due to improvements from admission
to discharge. However, for depression, we also found sig-
nificant differences between discharge and follow-up indi-
cating some deterioration (F = 20.7; d.f. = 1, 58; p !
0.001). For the other variables, improvements could be
maintained from discharge until the 1-year follow-up
assessment. Some variables also changed between pre-
treatment and admission (disability, MI, depression); this
may reflect some relief after admission.
For most variables, the mean scores indicated higher
psychopathology in the group of patients with panic disor-
der and comorbid major depression. For three variables, a
significant main effect for group underlined this notion
(disability, agoraphobic cognitions, depression). How-
ever, for none of the variables a significant group ! time
effect was found. This indicated that patients of both
groups showed comparable improvement.
As the changes between admission and discharge may
depend on severity, we reanalyzed those variables with
group differences using analysis of covariance with the
baseline scores as covariates. If baseline scores were con-
sidered in this way, the group did not differ on scores at
the end of treatment for the reanalyzed variables disabili-
ty, agoraphobic cognitions and depression. This fact un-
derlined again that both groups improved to a compara-
ble degree.
Thirteen patients received additional diagnoses of per-
sonality disorders. Therefore, we compared treatment
effects (admission vs. discharge) using analyses of covar-
iance with personality disorder as covariate. For some
variables, significant main effects for personality disorder
were found indicating higher severity in patients with per-
sonality disorders (depression F = 5.0; d.f. = 1, 62; p !
4.1*
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Table 2. Panic disorder with and without
major depression Without MD
mean SD
With MD
mean SD
ANOVA
group time G ! T
Disability
53.3*** 0.1
Pretreatment 7.34 1.85 8.60 2.37 P-A, A-D
Admission 6.05 2.50 7.77 2.38
Discharge 4.64 2.29 4.82 2.28 (8.0**) (59.8***) (0.1)
(4.81 2.31 5.59 2.79) (P-A, A-D)
1 year later 4.43 2.82 6.07 2.84
(4.86 2.94 6.53 3.02)
MI (alone) 2.3 53.6*** 2.1
Pretreatment 3.19 1.02 3.62 1.02 P-A, A-D
Admission 2.91 1.11 3.62 1.06
Discharge 2.04 0.90 2.44 0.91 (9.1**) (59.7***) (5.7*)
(2.04 0.90 2.81 1.10) (P-A, A-D,
1 year later 2.13 1.07 2.79 1.03 D-F)
(2.23 1.09 3.05 1.11)
MI (accompanied) 3.3 40.4*** 0.0
Pretreatment 2.70 0.97 2.87 1.03 P-A, A-D
Admission 2.32 0.95 2.90 1.11
Discharge 1.58 0.56 1.95 0.81 (4.0*) (40.6***) (0.5)
(1.71 0.73 2.23 1.01) (P-A, A-D,
1 year later 1.80 0.87 2.20 1.10 D-F)
(1.96 0.93 2.38 1.16)
ACQ 4.9* 8.0*** 0.1
Pretreatment 2.27 0.57 2.43 0.58 A-D
Admission 2.11 0.61 2.61 0.81
Discharge 1.97 0.66 2.07 0.83 (7.4**) (11.4**) (0.6)
(1.94 0.65 2.13 0.81) (A-D)
1 year later 1.91 0.63 2.36 0.95
(1.95 0.62 2.33 0.88)
BSQ 3.8 17.7*** 0.6
Pretreatment 2.88 0.61 3.09 0.73 A-D
Admission 2.81 0.73 3.37 0.73
Discharge 2.45 0.83 2.56 0.80 (6.1*) (14.3***) (0.0)
(2.46 0.81 2.74 0.82) (A-D)
1 year later 2.45 0.82 2.90 0.89
(2.50 0.81 2.89 0.84)
Depression (CES-D) 15.2*** 27.1*** 2.9
Pretreatment 28.16 10.06 38.03 11.00 P-A, A-D,
Admission 24.34 9.83 35.03 9.23 D-F
Discharge 18.59 11.16 22.62 12.19 (16.0***) (26.6***) (1.4)
(19.05 10.60 24.68 12.40) P-A, A-D,
1 year later 22.34 12.31 32.57 13.81 D-F)
(23.61 12.40 31.79 13.78)
* p ! 0.05; ** p ! 0.01; *** p ! 0.001. Degrees of freedom are the same for all three
analyses (c.f. 1, 55 for CES-D). Figures in parentheses are the results of the ITT. In the case of
significant effects for time, pairwise comparisons of adjacent assessment points were com-
puted. P-A = Significant change from pretreatment to admission; A-D = significant change
from admission to discharge; D-F = significant change from discharge to 1-year follow-up;
G ! T = group ! time; MD = major depression.
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0.05; BSQ F = 6.0; d.f. = 1, 52; p ! 0.02). Personality dis-
orders did not influence the degree of improvement dur-
ing therapy nor the changes after discharge (no significant
interaction with time).
Table 2 also includes the estimated scores when ITT
was done. As expected, the estimated scores for discharge
and 1-year follow-up were somewhat worse, especially for
the variables ‘disability’ and ‘mobility alone’. However,
the striking effects for time confirmed again the improve-
ment between admission and discharge. The more conser-
vative approach of ITT led to a significant deterioration
after discharge for the variables mobility and depression.
However, scores at follow-up continue to be lower than at
pretreatment or at admission. Due to the larger sample
size of the ITT compared to standard analyses, the main
effect for group is even more pronounced. While nearly all
interactions between group and time rested nonsignifi-
cant, less treatment success for the comorbidity group was
found for the variable mobility alone.
Number of Panic Attacks at Follow-Up
Of the patients with panic disorder without major
depression, 28 of 38 (74%) did not report any panic attack
in the last 7 days before the follow-up interview. Of the
patients with panic disorder with major depression, just
43% (10 of 23) did not report any panic attack. The differ-
ence between both groups reached statistical significance
(¯2 = 5.6; d.f. = 1; p ! 0.05).
Disability to Work
Table 1 showed that the samples examined produced
high socioeconomic costs due to disability days. At follow-
up, we asked the patients to rate the ability to work at a
full-time job. Sixty-four percent of patients without major
depression at admission and 37% of patients with major
depression rated themselves as capable of working (¯2 =
4.5, d.f. = 1; p ! 0.05). At the day of the follow-up assess-
ment, 16% of the pure panic group and 32% of the comor-
bidity group took sick pay (¯2 = 6.5; d.f. = 1; p ! 0.01).
Effects of Medication
Some patients received concurrent drug treatment.
The rates for the panic group (first score) and for the panic
and depression group (second score) were as follows: anti-
depressants at admission 33 versus 30% (mean dosage of
tricyclics per die: 88.0 mg); antidepressants at discharge
10 versus 21% (mean dosage of tricyclics per die:
99.6 mg); benzodiazepines at admission 5 versus 18%;
benzodiazepines at discharge 0 versus 3%. The primary-
care physicians’ prescriptions of medication were as-
sessed at pretreatment and at follow-up. Patients with
comorbid depression showed a trend to get more medica-
tion at pretreatment (antidepressants 57 vs. 41%; benzo-
diazepines 37 vs. 23%). However, none of these compari-
sons reached significance. For antidepressants and benzo-
diazepines, we found a significant reduction from pre-
treatment to follow-up (antidepressants 50 vs. 31%; ¯2 =
6.6; d.f. = 1; p ! 0.01; benzodiazepines 27 vs. 10%; ¯2 =
7.7; p ! 0.01).
The ANOVA of the questionnaire data were repeated
using ‘taking antidepressants at admission’ as covariate.
All within-subject comparisons between admission and
discharge continued to be significant (factor time) under-
lining the therapeutic improvement. However, some
group differences disappeared (for disability F = 1.6; for
ACQ F = 2.8; both n.s.). No interaction between group
and time reached significance, as in the analysis above.
Thus, also the covariate ‘taking antidepressants’ did not
have a significant influence on the patterns of change.
Effects of Lifetime Comorbidity with Major
Depression
Of the 45 panic patients without current major depres-
sion, 23 had a history of lifetime major depression. Those
patients were compared to the 22 patients with neither
current nor lifetime major depression. All variables indi-
cated significant improvements during treatment, but no
significant interaction effect for diagnostic group ! as-
sessment point. For the follow-up period, we did not find
any significant effects for the following variables: disabili-
ty, agoraphobic cognitions (ACQ), avoidance behavior
(MI alone), depression (CES-D), body sensations (BSQ).
For the variable ‘mobility accompanied MI’, there is a sig-
nificant main effect for diagnostic group indicating higher
scores for the group with comorbid lifetime major depres-
sion (F = 7.2; p ! 0.05), a significant effect for course after
discharge (F = 6.7; p ! 0.05), and a significant interaction
(F = 8.3; p ! 0.01) which indicates that the noncomorbid
group can maintain its benefits, while the group with a
lifetime diagnosis of major depression showed higher
scores at follow-up compared to discharge. The rates of
panic-free patients at follow-up did not differ significantly
between both groups (77 vs. 69%; n.s.).
Discussion
As Blanes and Raven [27] pointed out, most studies on
the psychological management of panic disorder excluded
patients with comorbid depression or included only a low
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rate of comorbid depressive patients. Comorbidity of anx-
iety and depressive disorders has been associated with
premature termination of treatment, a longer time to
recovery, and poor responses to psychotherapy or phar-
macotherapy [3]. The purpose of the present study was to
evaluate the possible effects of CBT in panic-disordered
patients with and without current major depression. Con-
trary to the results mentioned above, the investigated
inpatient treatment approach found high acceptance in
our patients with no cases of premature termination. This
is of major importance as our sample was not specifically
selected for a scientific treatment study, but was treated in
a setting of routine clinical care. Thus, CBT is not only
effective in controlled scientific trials but is also a useful
tool for inpatient health care settings.
Our sample had some features often associated with
bad outcome such as high agoraphobia scores, severe ago-
raphobic avoidance, high depression scores even in the
absence of current major depression, a history of multiple
treatments and a high rate of patients with disability to
work [5, 17, 28]. Further evidence for this statement came
from the questionnaire data indicating severe agoraphob-
ic avoidance (MI) and severe cognitive distortions (BSQ,
ACQ) even in comparison with other samples of panic
patients [24].
Some authors [16, 29] mentioned that comorbidity of
anxiety and depressive disorder is correlated with a severer
psychopathology. This assumption was confirmed by our
results comparing patients with panic disorder with and
without comorbid major depression at pretreatment. The
comorbidity group showed higher disability, higher scores
for panic-related symptoms, a higher rate of a history of
inpatient treatment and, of course, higher depression
scores. However, it is necessary to clarify the interaction of
depression and panic in the comorbidity group. Both disor-
ders may be reciprocal risk factors. Depression can alter
the perception of interoceptive signals which may be a risk
factor for panic attacks [30], while the limitations of mobil-
ity may enhance the risk for depression. A depressive cog-
nitive style may also amplify the ‘fear of fear’, a feature
associated with the development of panic attacks. Further-
more, both disorders may share common biological as well
as psychological risk factors. Despite these possible com-
mon features, depression and panic disorder can be dis-
criminated on variables of affect and cognition [31].
Laberge et al. [32] claimed that moderate secondary
depression is not an obstacle to effective treatment of
moderate panic disorder with CBT. However, the power
of the study is insufficient to demonstrate possible differ-
ences between panic-disordered patients with and with-
out comorbid major depression (8 vs. 7 patients). Yet our
results confirmed the assumption of Laberge et al. [32]. In
nearly all psychopathological variables, the comorbidity
group responded similarly to our treatment as the group
with panic only. The comorbidity group had a higher psy-
chopathology at the first assessment and also had higher
scores at the end of treatment; however, the treatment
response was comparable between both groups.
A further hypothesis may claim that the comorbidity
group has more relapses during the follow-up period than
the pure panic-disordered group. In fact, the group with-
out major depression reported a rate of 74% of persons
being panic free in the last 7 days, while the group with
comorbid current major depression reported only a rate of
43% of patients being panic free. However, we found no
interaction for any of the variables between diagnostic
group and assessment point at follow-up except in the ITT
for mobility (alone). Thus, the higher rate of patients with
continuing panic attacks in the comorbidity group may be
in part the result of higher pathology at all assessment
points. For the variable depression and, in part, for the
variable mobility, however, we found significantly higher
scores at follow-up compared to discharge after all in the
comorbidity group of patients with panic disorder and
major depression.
In sum, the CBT helped to improve the well-being even
in the case of comorbidity of panic attacks with major
depression. However, the end-state functioning of the
comorbidity group was lower than that of the pure panic
group. This is especially due to the group with comorbid
major depression at admission, not to the patients with a
lifetime history but without current depression at the
beginning of the treatment. Therefore, there is a major
need to develop treatment approaches for patients not
only with panic disorder, but with current comorbid
major depression.
Recent studies claimed that comorbidity of panic dis-
order with depression is not a rare incidence, but seems to
be common [14, 15, 33]. A combination of CBT and anti-
depressant drug therapy for patients with panic disorders
and major depression may be one approach worth evalu-
ating. However, comorbidity is a negative predictor also
in pharmacological trials [3, 34]. A combined treatment
package with CBT for panic attacks and CBT for depres-
sive episodes may be a second perspective. Despite these
considerations, it is possible that the best treatment for
combined disorders is not a combined therapy but a pure
approach.
Our study has some shortcomings limiting the strength
of the interpretation. First, we did not completely stan-
Panic Disorder and Major Depression Psychother Psychosom 2000;69:70–78 77
dardize the treatment packages. Therefore, it is inappro-
priate to attribute the outcome to the panic management
group, but the outcome should be attributed to the com-
plete treatment package. Secondly, we did not use a pure
control group to compare our results with spontaneous
fluctuations. However, as we collected the data over a
half-year waiting period and as our patients had high
chronicity, it seems improbable that the spontaneous
course would be as efficient as our treatment package was.
Furthermore, the rate of spontaneous remissions in panic
disorder is low [35]. Third, our patients of the panic group
without current major depression also reached high scores
for depression. This group seemed comparable to many
samples of patients treated in published clinical trials. In
fact, it showed comparable rates of panic-free patients to
other studies. Fourth, as a result of liberal inclusion crite-
ria, additional psychopathological problems were present
in our samples. Comorbid problems, such as somatoform
disorders, are typical for settings of routine care [36].
Therefore, this aspect underlines our aim to investigate
unselected groups.
The present study took place in a German inpatient
setting. The selection of the treatment setting in interven-
tion studies limits the generalizability of results in general.
Despite the fact that many panic patients receive short-
term inpatient treatment in psychiatric units, the applica-
tion of inpatient CBT is uncommon for most parts of the
world. The selection bias of an inpatient setting includes
higher rates of comorbidity and chronicity. Therefore, our
results may be valid for the severely disabled persons with
panic disorders, but perhaps less valid for mediumly dis-
abled outpatients. The contents of our inpatient treat-
ments did not seem to be substantially different from that
of outpatient treatments (such as from Telch et al. [8]).
However, our treatments were more condensed.
Finally, while we have found striking effects for most
variables, we found smaller effects for the scores of the
cognition questionnaires. This may be due to differences
of sensitivity of the questionnaire. However, in this highly
chronified sample, cognitions may be more difficult to
change than behavior. Furthermore, our samples in-
cluded high rates of patients with additional social pho-
bia. Poulton and Andrews [37] claimed that anxiety-spe-
cific cognitions in social phobia are highly treatment resis-
tant.
However, we should also consider the critique of Sal-
kovskis et al. [38] who point out that inappropriate threat
beliefs of panic patients may be sustained rather than
modified by some panic management techniques which
were also used in our approach (such as breathing retrain-
ing). Moreover, we used a group therapy approach while
most studies were run using individual therapies. While
the group approach is very cost-effective and has some
advantages (such as social support, provocation of more
symptoms during hyperventilation test), it may be less
effective to modify specific catastrophic cognitions.
While optimistic descriptions of treatment success in
panic disorder were typical for earlier trials, in the last
years, the focus has changed to emphasize the significance
of subclinical symptoms. Fava and Mangelli [39] pointed
out that prodromal symptoms before developing the com-
plete features of panic, as well as residual symptoms after
successful treatment, are very common. Typical residual
symptoms were social impairment, subclinical anxiety
symptoms and dependence. Even after successful treat-
ment, it is only a minority of patients who are completely
free of symptoms. Our study may be a further step to
describe possibilities, but also shortcomings, of current
treatment approaches in routine clinical care.
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